Non-Insulin Therapies for Diabetes Market, by Drug Class (Biguanides, Sulfonylureas Thiazolidinedione’s, Alpha-Glucosidase Inhibitors, DPP-4 Inhibitors, GLP-1 Analogs, and Sodium-glucose co-transporter-2 (SGLT2) inhibitors), by Route of Administration (Oral and Injectable), by Distribution Channel (Retail Pharmacy, Hospital Pharmacy, and Online Pharmacy), and by Region – Size, Share, Outlook, and Opportunity Analysis, 2022-2028
Select a license type that suits your business needs
Single User License
US$ 4,500
US$ 3,500
Three thousand five hundred dollars
Frequently purchased
Multi User License
US$ 7,000
US$ 5,500
Five thousand five hundred dollars
Corporate User License
US$ 10,000
US$ 7,500
Seven thousand five hundred dollars
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients